4.4 Article

Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

期刊

LANCET RHEUMATOLOGY
卷 4, 期 9, 页码 E603-E613

出版社

ELSEVIER
DOI: 10.1016/S2665-9913(22)00192-8

关键词

-

资金

  1. American College of Rheumatology
  2. European Alliance of Associations for Rheumatology

向作者/读者索取更多资源

This study investigated the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease. The findings suggest that air pollution, proportion of the population aged 65 years or older, and population mobility are independently associated with higher odds of mortality. Factors such as number of hospital beds, human development index, government response stringency, and follow-up time are independently associated with lower odds of mortality.
Background Differences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally. Methods In this observational study, we derived individual-level data on adults (aged 18-99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death. Findings 14 044 patients from 23 countries were included in the analyses. 10 178 (72. 5%) individuals were female and 3866 (27.5%) were male, with a mean age of 54.4 years (SD 15.6). Air pollution (odds ratio 1.10 per 10 mu g/m(3) [95% CI 1.01-1.17]; p=0.0105), proportion of the population aged 65 years or older (1. 19 per 1% increase [1.10-1.30]; p<0.0001), and population mobility (1.03 per 1% increase in number of visits to grocery and pharmacy stores [1.02-1.05]; p<0. 0001 and 1.02 per 1% increase in number of visits to workplaces [1 .00- 1.03]; p=0.032) were independently associated with higher odds of mortality. Number of hospital beds (0.94 per 1-unit increase per 1000 people [0.88-1.00]; p= 0.046), human development index (0.65 per 0.1-unit increase [0. 44-0.96]; p=0.032), government response stringency (0.83 per 10-unit increase in containment index [ 0.74-0.93]; p=0.0018), as well as follow-up time (0.78 per month [0.69- 0.88]; p<0.0001) were independently associated with lower odds of mortality. These factors sufficiently explained country-level variations in death attributable to COVID-19 (intraclass correlation coefficient 1.2% [0.1-9.5]; p=0. 14). Interpretation Our findings highlight the importance of environmental and societal factors as potential explanations of the observed regional disparities in COVID-19 outcomes among people with rheumatic disease and lay foundation for a new research agenda to address these disparities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al

Kimme L. Hyrich, Martin Schaefer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F. Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

Ryan M. Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, Darren Plant, Anne Barton

Summary: This study suggests that higher levels of TNF-a inhibitor serum drug levels (SDLs) are associated with good treatment response in fully adherent patients. Interventions to improve SDLs, such as encouraging adherence, may improve treatment response. The identified SDL cut-offs for adalimumab and certolizumab may be useful in clinical practice.

RHEUMATOLOGY (2023)

Article Rheumatology

Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

Manuel F. Ugarte-Gil, Graciela S. Alarcon, Andrea M. Seet, Zara Izadi, Anna D. Montgomery, Ali Duarte-Garcia, Emily L. Gilbert, Maria O. Valenzuela-Almada, Leanna Wise, Jeffrey A. Sparks, Tiffany Y. -T. Hsu, Kristin M. D'Silva, Naomi J. Patel, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Zachary Wallace, Lindsay Jacobsohn, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Pedro M. Machado, Philip C. Robinson, Milena Gianfrancesco, Jinoos Yazdany

Summary: A study on individuals with SLE in the US found that Black and Hispanic patients had higher odds of experiencing more severe COVID-19 outcomes compared to White patients, which may be attributed to socioeconomic and health disparities.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Risk of COVID-19 Among Unvaccinated and Vaccinated Patients With Rheumatoid Arthritis: A General Population Study

Hui Li, Zachary S. Wallace, Jeffrey A. Sparks, Na Lu, Jie Wei, Dongxing Xie, Yilun Wang, Chao Zeng, Guanghua Lei, Yuqing Zhang

Summary: Patients with rheumatoid arthritis (RA) are at higher risks of SARS-CoV-2 infection and severe outcomes even after COVID-19 vaccination. It is necessary to implement booster COVID-19 vaccinations and other preventive strategies for patients with RA.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study

Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen

Summary: This study evaluated the real-world persistence and effectiveness of the IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. The results showed that the proportion of patients still on their initial treatments after 3 years was similar with ustekinumab and TNFi, but ustekinumab had a lower rate of adverse events.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists

Agnete Overgaard Donskov, Sarah Louise Mackie, Ellen Margrethe Hauge, Carlos Enrique Toro-Gutierrez, Ib Tonder Hansen, Andrea Katharina Hemmig, Aatke Van der Maas, Tamer Gheita, Berit Dalsgaard Nielsen, Karen M. J. Douglas, Richard Conway, Elena Rezus, Bhaskar Dasgupta, Sara Monti, Eric L. Matteson, Sebastian E. Sattui, Mark Matza, Vanessa Ocampo, Margarita Gromova, Rebecca Grainger, Andrea Bran, Simone Appenzeller, Annelise Goecke, Nelly Colman, Helen Keen, Masataka Kuwana, Latika Gupta, Babur Salim, Ghita Harifi, Mariam Erraoui, Nelly Ziade, Nizar Abdulateef Al-Ani, Adeola Ajibade, Johannes Knitza, Line Frolund, Max Yates, Victor R. Pimentel-Quiroz, Andre Marun Lyrio, Maria Sandovici, Kornelis S. M. Van der Geest, Toby Helliwell, Elisabeth Brouwer, Christian Dejaco, Kresten Krarup Keller

Summary: A global survey of general practitioners and rheumatologists revealed that a significant proportion of patients with polymyalgia rheumatica (PMR) are not referred for diagnosis or correctly managed, which has implications for clinical trial recruitment.

RHEUMATOLOGY (2023)

Article Rheumatology

Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020

Katinka Albrecht, Anja Strangfeld, Ursula Marschall, Johanna Callhoff

Summary: This study investigates the prevalence, incidence, and medication of interstitial lung disease (ILD) among individuals with rheumatoid arthritis (RA) in Germany. It finds that RA-ILD is rare and mainly affects elderly individuals. Although there is no trend in incidence, treatment strategies have expanded, and specialist care is necessary to provide disease-specific therapies.

RMD OPEN (2023)

Article Oncology

Calprotectin in Patients with Rheumatic Immunomediated Adverse Effects Induced by Checkpoints Inhibitors

Beatriz Frade-Sosa, Chafik Alejandro Chacur, Josep M. Auge, Andres Ponce, Juan C. Sarmiento-Monroy, Ana Belen Azuaga, Nuria Sapena, Julio Ramirez, Virginia Ruiz-Esquide, Rosa Morla, Sandra Farietta, Patricia Corzo, Juan D. Canete, Raimon Sanmarti, Jose A. Gomez-Puerta

Summary: This study aimed to evaluate the serum levels of calprotectin in patients with rheumatic immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) treatment. The results showed that calprotectin can serve as a marker of inflammatory activity in patients with rheumatic irAEs.

CANCERS (2023)

Article Rheumatology

Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study

Kaitlin R. McCarter, Taylor Wolfgang, Senada Arabelovic, Xiaosong Wang, Kazuki Yoshida, Emily P. Banasiak, Grace Qian, Emily N. Kowalski, Kathleen M. M. Vanni, Nicole R. LeBoeuf, Elizabeth Buchbinder, Lydia Gedmintas, Lindsey A. MacFarlane, Deepak A. Rao, Nancy A. Shadick, Ellen M. Gravallese, Jeffrey A. Sparks

Summary: Patients with pre-existing rheumatoid arthritis initiating immune checkpoint inhibitors had similar risk of mortality and severe immune-related AEs as matched comparators. Although patients with pre-existing rheumatoid arthritis were more likely to have immune-related AEs, this finding was mostly due to mild rheumatoid arthritis flares. These results suggest that this patient population can safely receive immune checkpoint inhibitors for cancer treatment.

LANCET RHEUMATOLOGY (2023)

Article Rheumatology

Systemic sclerosis associated interstitial lung disease: a survey of current practices in France

Amelie Nicolas, Sylvie Leroy, Luc Mouthon, Yurdagul Uzunhan, Vincent Cottin, Arsene Mekinian, Viviane Queyrel, Eric Hachulla, Benoit Gachet, David Launay, Nihal Martis

Summary: This study provides an overview of the diagnostic approaches, follow-up, and treatment strategies used in France for the management of SSc-associated ILD. The results highlight the heterogeneity and gaps in current clinical practices, calling for improvement and standardization.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2023)

Meeting Abstract Rheumatology

PRELIMINARY STEPS FOR MULTICRITERIA DECISION ANALYSIS PROCESS IN THE DEVELOPMENT OF CLASSIFICATION CRITERIA FOR ANTISYNTHETASE SYNDROME: THE USE OF 1000MINDS FOR THE CLASS PROJECT.

Giovanni Zanframundo, Sara Faghihi-Kashani, Paul Hansen, Carlo A. Scire, Garifallia Sakellariou, Lorenzo Cavagna, Rohit Aggarwal

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2023)

Article Rheumatology

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith

Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.

ANNALS OF THE RHEUMATIC DISEASES (2023)

暂无数据